SCHEMBL17024101

SCHEMBL17024101

CC(C)(C)c1ccc(OCC(O)[CH]O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.50
▸ GAA P10253 1/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ LMNA P02545 2/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ KDM4E B2RXH2 3/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ HTT P42858 2/20 0.45
▸ MAOB P27338 1/20 0.45
▸ AOC3 Q16853 1/20 0.45
▸ HIF1A Q16665 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ AR P10275 1/20 0.44
▸ APP P05067 1/20 0.42
▸ NR4A2 P43354 1/20 0.42
▸ RXRA P19793 1/20 0.42
▸ RXRB P28702 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17024094 0.85 NPC1 (0.45) MAPTNPC1RAB9AHTTMAOB
SCHEMBL17024108 0.84 CYP3A4 (0.56) MAPTSMN1; SMN2LMNAKDM4EHTT
SCHEMBL17024104 0.84 KMT2A (0.55) GAASMN1; SMN2LMNAKDM4EHTT
SCHEMBL17024102 0.83 MAPT (0.48) MAPTGAASMN1; SMN2LMNAHSD17B10
SCHEMBL15677148 0.82 MAPT (0.63) MAPTGAASMN1; SMN2LMNAHSD17B10
SCHEMBL2044174 0.80 LMNA (0.60) MAPTGAASMN1; SMN2LMNAHSD17B10
SCHEMBL11036255 0.79 MAPT (0.52) MAPTGAASMN1; SMN2LMNAHSD17B10
SCHEMBL17024114 0.79 LMNA (0.46) MAPTGAASMN1; SMN2LMNAHSD17B10
SCHEMBL17024095 0.77 KMT2A (0.50) MAPTGAASMN1; SMN2LMNAKDM4E
SCHEMBL13761600 0.77 AR (0.69) MAPTGAASMN1; SMN2LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2915796-A1 PROPYL-PHENYL-ETHER DERIVATIVE AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT, AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE Seiwa Kasei Company, Limited (JP) 2015-09-09 — — EP disclosed
US-20150238401-A1 PROPYL-PHENYL-ETHER DERIVATIVE, AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE SEIWA KASEI COMPANY, LIMITED (JP) 2015-08-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150238401-A1 PROPYL-PHENYL-ETHER DERIVATIVE, AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE TYR, MITF, MC1R MAPT 1564/4885GAA 3431/4885SMN1; SMN2 4407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback